AN2 Therapeutics Reports Phase 3 Portion Of Previously Terminated EBO-301 Study Data; Outlines Future Milestones From Boron Chemistry Pipeline

Author: Benzinga Newsdesk | May 01, 2025 04:01pm

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease

Extensive enabling NTM data provides potential path forward in M. abscessus lung disease

Company focus remains centered on boron chemistry pipeline with initiation of high impact clinical programs in infectious diseases and an emerging oncology portfolio

Initiated start up activities for Phase 1 first in human study in healthy volunteers of AN2-502998, under development to treat chronic Chagas disease

Topline data for standard-of-care melioidosis observational trial expected in 2Q25; Phase 2 study planned for 2H25 with goal of reducing mortality from observed rates approaching 40%

First oncology compound(s) from boron chemistry platform on track to advance into development in 2H25; targets best-in-class profiles with fully owned IP; novel oncology compounds target ENPP1, PI3Kα and other undisclosed targets for solid tumor indications

Company extends cash runway into 2028, implements strategic measures to optimize operations and enhance shareholder value

Posted In: ANTX